DYADIC INTERNATIONAL INC Research and Development Expense
DYADIC INTERNATIONAL INC (DYAI) reported Research and Development Expense of $332.62 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- DYADIC INTERNATIONAL INC research and development expense for the quarter ending 2026-06-30 was $332.62K, a 47.15% decline year-over-year.
- DYADIC INTERNATIONAL INC research and development expense for the quarter ending 2026-03-31 was $476.07K, a 3.82% decline year-over-year.
- DYADIC INTERNATIONAL INC research and development expense for the quarter ending 2025-12-31 was $458.44K, a 15.99% decline year-over-year.
- DYADIC INTERNATIONAL INC research and development expense for the quarter ending 2025-09-30 was $571.87K, a 24.25% increase year-over-year.
- DYADIC INTERNATIONAL INC research and development expense for fiscal 2025 was $2.15M, a 5.40% increase from fiscal 2024.
- DYADIC INTERNATIONAL INC research and development expense for fiscal 2024 was $2.04M, a 38.00% decline from fiscal 2023.
- DYADIC INTERNATIONAL INC research and development expense for fiscal 2023 was $3.30M, a 26.75% decline from fiscal 2022.
- DYADIC INTERNATIONAL INC research and development expense for fiscal 2022 was $4.50M, a 46.36% decline from fiscal 2021.
USD
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $332.62K 10-Q · filed 2026-08-12 | $808.69K 10-Q · filed 2026-08-12 | $1.27M derived: sum of 3 quarters · filed 2026-08-12 | $1.84M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $476.07K 10-Q · filed 2026-05-13 | $934.50K derived: sum of 2 quarters · filed 2026-05-13 | $1.51M derived: sum of 3 quarters · filed 2026-05-13 | $2.14M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $458.44K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.03M derived: sum of 2 quarters · filed 2026-03-25 | $1.66M derived: sum of 3 quarters · filed 2026-08-12 | $2.15M 10-K · filed 2026-03-25 | |
| 2025-09-30 | $571.87K 10-Q · filed 2025-11-12 | $1.20M derived: sum of 2 quarters · filed 2026-08-12 | $1.70M 10-Q · filed 2025-11-12 | $2.24M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $629.38K 10-Q · filed 2026-08-12 | $1.12M 10-Q · filed 2026-08-12 | $1.67M derived: sum of 3 quarters · filed 2026-08-12 | $2.13M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $494.98K 10-Q · filed 2026-05-13 | $1.04M derived: sum of 2 quarters · filed 2026-05-13 | $1.50M derived: sum of 3 quarters · filed 2026-05-13 | $2.02M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $545.66K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.01M derived: sum of 2 quarters · filed 2026-03-25 | $1.52M derived: sum of 3 quarters · filed 2026-03-25 | $2.04M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $460.24K 10-Q · filed 2025-11-12 | $975.87K derived: sum of 2 quarters · filed 2025-11-12 | $1.50M 10-Q · filed 2025-11-12 | $2.35M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $515.63K 10-Q · filed 2025-08-13 | $1.04M 10-Q · filed 2025-08-13 | $1.89M derived: sum of 3 quarters · filed 2025-08-13 | $2.61M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $522.72K 10-Q · filed 2025-05-14 | $1.38M derived: sum of 2 quarters · filed 2025-05-14 | $2.09M derived: sum of 3 quarters · filed 2025-05-14 | $3.01M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $852.80K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $1.57M derived: sum of 2 quarters · filed 2025-03-26 | $2.49M derived: sum of 3 quarters · filed 2025-03-26 | $3.30M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $716.35K 10-Q · filed 2024-11-12 | $1.63M derived: sum of 2 quarters · filed 2024-11-12 | $2.44M 10-Q · filed 2024-11-12 | $3.03M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $917.55K 10-Q · filed 2024-08-13 | $1.73M 10-Q · filed 2024-08-13 | $2.31M derived: sum of 3 quarters · filed 2024-08-13 | $3.06M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $810.57K 10-Q · filed 2024-05-14 | $1.39M derived: sum of 2 quarters · filed 2024-05-14 | $2.14M derived: sum of 3 quarters · filed 2024-05-14 | $3.97M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $584.12K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.33M derived: sum of 2 quarters · filed 2024-03-28 | $3.16M derived: sum of 3 quarters · filed 2024-03-28 | $4.50M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $743.59K 10-Q · filed 2023-11-08 | $2.57M derived: sum of 2 quarters · filed 2023-11-08 | $3.92M 10-Q · filed 2023-11-08 | $6.39M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | $1.83M 10-Q · filed 2023-08-09 | $3.17M 10-Q · filed 2023-08-09 | $5.65M derived: sum of 3 quarters · filed 2023-08-09 | $7.55M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $1.34M 10-Q · filed 2023-05-10 | $1.34B 10-Q · filed 2022-05-12 | $3.82M derived: sum of 2 quarters · filed 2023-05-10 | $5.72M derived: sum of 3 quarters · filed 2023-05-10 | $7.93M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $4.38M derived: sum of 2 quarters · filed 2023-03-29 | $6.58M derived: sum of 3 quarters · filed 2023-03-29 | $8.39M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $1.90M 10-Q · filed 2022-11-10 | $4.11M derived: sum of 2 quarters · filed 2022-11-10 | $5.92M 10-Q · filed 2022-11-10 | $1.81B derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $2.21M 10-Q · filed 2022-08-10 | $4.02M 10-Q · filed 2022-08-10 | $1.81B derived: sum of 3 quarters · filed 2022-08-10 | $1.81B derived: sum of 4 quarters · filed 2022-08-10 | |
| 2021-03-31 | $1.81B 10-Q · filed 2022-05-12 | $1.81M 10-Q · filed 2021-05-13 | $1.81B derived: sum of 2 quarters · filed 2022-05-12 | $1.81B derived: sum of 3 quarters · filed 2022-05-12 | $1.81B derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $2.00M derived: sum of 2 quarters · filed 2022-03-29 | $3.11M derived: sum of 3 quarters · filed 2022-03-29 | $3.87M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $986.05K 10-Q · filed 2021-11-10 | $2.10M derived: sum of 2 quarters · filed 2021-11-10 | $2.86M 10-Q · filed 2021-11-10 | $3.59M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $1.12M 10-Q · filed 2021-08-12 | $1.87M 10-Q · filed 2021-08-12 | $2.61M derived: sum of 3 quarters · filed 2021-08-12 | $3.45M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $755.45K 10-Q · filed 2021-05-13 | $1.49M derived: sum of 2 quarters · filed 2021-05-13 | $2.33M derived: sum of 3 quarters · filed 2021-05-13 | $3.15M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $735.64K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $1.58M derived: sum of 2 quarters · filed 2021-03-30 | $2.40M derived: sum of 3 quarters · filed 2021-03-30 | $3.09M 10-K · filed 2021-03-30 | |
| 2019-09-30 | $841.34K 10-Q · filed 2020-11-12 | $1.66M derived: sum of 2 quarters · filed 2020-11-12 | $2.35M 10-Q · filed 2020-11-12 | $2.80M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $818.24K 10-Q · filed 2020-08-13 | $1.51M 10-Q · filed 2020-08-13 | $1.96M derived: sum of 3 quarters · filed 2020-08-13 | $2.43M derived: sum of 4 quarters · filed 2020-08-13 | |
| 2019-03-31 | $692.37K 10-Q · filed 2020-05-14 | $1.14M derived: sum of 2 quarters · filed 2020-05-14 | $1.62M derived: sum of 3 quarters · filed 2020-05-14 | $2.22M derived: sum of 4 quarters · filed 2020-05-14 | |
| 2018-12-31 | $446.91K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $923.54K derived: sum of 2 quarters · filed 2020-03-30 | $1.52M derived: sum of 3 quarters · filed 2020-03-30 | $2.10M 10-K · filed 2020-03-30 | |
| 2018-09-30 | $476.63K 10-Q · filed 2019-11-13 | $1.08M derived: sum of 2 quarters · filed 2019-11-13 | $1.65M 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $601.20K 10-Q · filed 2019-08-13 | $1.18M 10-Q · filed 2019-08-13 | |||
| 2018-03-31 | $576.88K 10-Q · filed 2019-05-09 | ||||
| 2017-12-31 | $1.77M 10-K · filed 2019-03-27 |
EUR
| Period end | Research and Development Expense |
|---|---|
| 2025-09-30 | 187.94K EUR 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |